Bristol Myers gets regulatory clearance to close Mirati deal as FTC increases pressure on pharma M&A
Bristol Myers Squibb has the go-ahead from antitrust regulators to complete its $4.8 billion takeover of Mirati.
Increased FTC scrutiny has put large pharma mergers in the spotlight this year, including a months-long battle over Amgen’s $27.8 billion Horizon takeover and a recently dropped deal between Sanofi and Maze Therapeutics. The FTC finalized new guidance around merger review yesterday, replacing a decade-old framework.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
